Toggle Main Menu Toggle Search

Open Access padlockePrints

Allogeneic hematopoietic SCT for patients with autoimmune diseases

Lookup NU author(s): Dr Thomas Huegle, Professor Jaap Van Laar


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Allogeneic hematopoietic SCT (HSCT) ha s been used as treatment for single patients with autoimmune diseases (AD). To summarise currently available information, we analyzed all patients who underwent allogeneic HSCT for AD and who reported to the European Group for Blood and Marrow Transplantation (EBMT) data base. Thirty-five patients receiving 38 allogeneic transplantations for various hematological and non-hematological AD were identified. Four patients had had an allogeneic HSCT for a conventional hematological indication in the past. Fifty-five per cent of the transplantation procedures led to a complete clinical response of the refractory AD and 23% to at least a partial response. The median duration of response at the last follow-up was 70.7 (15.2-130) months. Three patients relapsed at a median of 12.3 months after HSCT. Treatment-related mortality at 2 years was 22.1% (95% CI: 7.3-36.9%). Two deaths were caused by progression of AD. The probability of survival at 2 years was 70%. No single factor predicting the outcome could be identified. The retrospective nature of this study and the heterogeneous, partly incomplete data are its limitations. However, allogeneic HSCT can induce remission in patients suffering from refractory AD. These data provide the basis for carefully conducted prospective trials. Bone Marrow Transplantation (2009) 44, 27-33; doi:10.1038/bmt.2008.424; published online 12 January 2009

Publication metadata

Author(s): Daikeler T, Hugle T, Farge D, Andolina M, Gualandi F, Baldomero H, Bocelli-Tyndall C, Brune M, Dalle JH, Ehninger G, Gibson B, Linder B, Lioure B, Marmont A, Matthes-Martin S, Nachbaur D, Schuetz P, Tyndall A, van Laar JM, Veys P, Saccardi R, Gratwohl A, EBMT

Publication type: Article

Publication status: Published

Journal: Bone Marrow Transplantation

Year: 2009

Volume: 44

Issue: 1

Pages: 27-33

ISSN (print): 0268-3369

ISSN (electronic): 1476-5365

Publisher: Nature Publishing Group


DOI: 10.1038/bmt.2008.424


Altmetrics provided by Altmetric


Funder referenceFunder name
Alexion Europe
Bristol Myers Squibb
Celegene International SARL
Chugai Sanofi-Aventis SNC
F Hoffmann-La Roche Ltd
Gambro BCT
GE Healthcare
Merck Sharp and Dohme
Miltenyl Biotec GmbH
Regional Cancer League and the Horton Foundation
Schering-Plough International Inc
Swiss Cancer League
ViroPharma Europe
Amgen Europe GmbH
Bayer Schering Pharma AG
Biosafe SA
Fresenius Biotech GmbH
Gilead Sciences UK
Pierre Fabre Medicament
3200B0-118176Swiss National Research Foundation
LSH-2002-2.2.0-3European Leukemia Net